Dexcom (Nasdaq:DXCM) recently announced the availability of its Dexcom One real-time continuous glucose monitor (CGM) in France.
The availability of the real-time CGM sensor comes via reimbursement. It brings the technology to half a million more people with diabetes in France. The company secured access to the platform for all patients two years and older with type 1 and type 2 diabetes undergoing intensive insulin therapy.
Dexcom One continuously monitors glucose levels in real-time, sending values wirelessly to a compatible smart device through the app or receiver, which then display trend arrows to show the speed and direction that glucose levels are heading. It also has a range of customizable alerts and access to the Clarity data management software to provide remote data sharing with HCPs. It uses the G6 hardware platform with a different software experience.
The San Diego-based company launched Dexcom One in the UK in April 2022, followed by a pharmacy channel rollout in August 2022. The system already launched in a handful of European countries at the end of 2021. It has availability in Bulgaria, Latvia, Estonia and Lithuania, too.
Launching the CGM platform in France offers patients access to a choice of real-time CGM sensors, the company said.
“We believe this is truly exciting news for people living with diabetes in France,” said Gérald Zammit, country director of Dexcom France. “Access to Dexcom real-time CGM sensors is now available to those who live with diabetes, who aren’t necessarily seen as ‘high risk’, but who can still greatly benefit from it. The launch of Dexcom One in France will help to make real-time CGM accessible to as many patients as possible.”